AsclepiX Therapeutics’ $35 Million Series A Financing

Choate represented Perceptive Xontogeny Venture Fund in the transaction.

AsclepiX Therapeutics, Inc. has closed a $35 million Series A financing led by Perceptive Xontogeny Venture Fund (“PXV Fund”) with participation from the Perceptive Life Sciences Fund, both funds managed by Perceptive Advisors, and existing investors Rapha Capital Management and Barer & Son Capital.

AsclepiX Therapeutics is a biopharmaceutical company that uses computational biology to identify potent peptide regulators of vascular homeostasis for the treatment of retinal and other important diseases.

AsclepiX Therapeutics is currently developing therapies for the treatment of diseases of the eye using novel peptides with the power to inhibit proven key disease pathways. The company’s lead compound, AXT107, is in development as a treatment for three eye disorders – diabetic macular edema, the “wet” form of age-related macular degeneration, and retinal vein occlusion – and a clinical trial could start by the end of 2020. AsclepiX also has three earlier-stage candidates in development for treating solid cancer tumors.

Choate represented Perceptive Xontogeny Venture Fund with a team led by Brian D. Goldstein, with Kevin M. Tormey, Charles E. Lyon, DPhil, Brian E. Reese, PhD, MBA, John Marshall Chambers, Dana W. Spigelman, Isaiah Neve, PhD.

Involved fees earner: Brian Goldstein – Choate; Charles Lyon – Choate; John Marshall Chambers – Choate; Isaiah Neve – Choate; Brian Reese – Choate; Dana Spigelman – Choate; Kevin Tormey – Choate;

Law Firms: Choate;

Clients: Perceptive Xontogeny Venture Fund;

Author: Ambrogio Visconti